Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Intravacc B V is engaged in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These actions are assigned to 2 distinct examiners, requiring the applicant to address the specific concerns of different individuals within the USPTO. The portfolio is situated within 1 distinct art unit, which centralizes the technical review of the pending matters.
OGUNBIYI, OLUWATOSIN A is identified as the busiest examiner, with 1 busiest examiner pending action. This indicates that the workload is split between the 2 distinct examiners. For a practitioner, the presence of 2 pending office actions in 1 distinct art unit suggests a consistent technical environment despite the involvement of multiple examiners.
Managing the 1 busiest examiner pending action with OGUNBIYI, OLUWATOSIN A will require a strategy that also considers the parallel prosecution of the other pending matter. The use of 1 distinct art unit may simplify the application of relevant prior art across the 2 pending office actions. This concentration within a single art unit allows for a more unified approach to the technical arguments presented to the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043595 | OMPA MUTATIONS ENHANCE OMV PRODUCTION IN BORDETELLA PERTUSSIS | OGUNBIYI, OLUWATOSIN A | 53d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18043595 | OMPA MUTATIONS ENHANCE OMV PRODUCTION IN BORDETELLA PERTUSSIS | OGUNBIYI, OLUWATOSIN A | 53d overdue |
| 17676877 | Modified hexa-acylated neisserial LPS | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18043595 | OMPA MUTATIONS ENHANCE OMV PRODUCTION IN BORDETELLA PERTUSSIS | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§112 | Non-Final OA | 53d overdue | Pending | Mar 01, 2023 |
| 17676877 | Modified hexa-acylated neisserial LPS | DICKENS, AMELIA NICOLE | 1645 | Other | Non-Final OA | — | Pending | Feb 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntravacc B V has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Oluwatosin A Ogunbiyi has the most, with 1 of Intravacc B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
